Third Rock Ventures’ Love Story With Cancer Immunotherapy Results In The Founding Of Jounce Therapeutics
This article was originally published in The Pink Sheet Daily
Executive Summary
The venture firm has pledged $47 million in funding to start-up Jounce Therapeutics to discover and develop biologic drugs for the treatment of cancer.
You may also be interested in...
Yervoy Survival Data From First-Line Study Sealed The Deal For FDA Approval
FDA’s approval of Bristol-Myers Squibb’s metastatic melanoma immunotherapy was granted only after looking outside the BLA for assurance that the biologic’s effect was robust and validated.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.